TD Private Client Wealth LLC Trims Position in Charles River Laboratories International, Inc. (NYSE:CRL)

TD Private Client Wealth LLC trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,022 shares of the medical research company’s stock after selling 320 shares during the quarter. TD Private Client Wealth LLC’s holdings in Charles River Laboratories International were worth $1,665,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Versant Capital Management Inc increased its stake in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. increased its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after acquiring an additional 115 shares during the period. ORG Wealth Partners LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the third quarter worth about $59,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $167.29 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a market capitalization of $8.55 billion, a price-to-earnings ratio of 1,115.26, a PEG ratio of 4.54 and a beta of 1.45. The company’s 50 day simple moving average is $166.11 and its 200 day simple moving average is $183.71. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $273.57.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 earnings per share. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Barclays lowered their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $190.00 to $170.00 in a research report on Friday. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).